<code id='2E567FF3B2'></code><style id='2E567FF3B2'></style>
    • <acronym id='2E567FF3B2'></acronym>
      <center id='2E567FF3B2'><center id='2E567FF3B2'><tfoot id='2E567FF3B2'></tfoot></center><abbr id='2E567FF3B2'><dir id='2E567FF3B2'><tfoot id='2E567FF3B2'></tfoot><noframes id='2E567FF3B2'>

    • <optgroup id='2E567FF3B2'><strike id='2E567FF3B2'><sup id='2E567FF3B2'></sup></strike><code id='2E567FF3B2'></code></optgroup>
        1. <b id='2E567FF3B2'><label id='2E567FF3B2'><select id='2E567FF3B2'><dt id='2E567FF3B2'><span id='2E567FF3B2'></span></dt></select></label></b><u id='2E567FF3B2'></u>
          <i id='2E567FF3B2'><strike id='2E567FF3B2'><tt id='2E567FF3B2'><pre id='2E567FF3B2'></pre></tt></strike></i>

          Home / entertainment / knowledge

          knowledge


          knowledge

          author:comprehensive    Page View:145

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In